Baseline demographic and medical characteristics
| . | All (n = 105) . | Exercise (n = 52) . | Control (n = 53) . | P . |
|---|---|---|---|---|
| Center | ||||
| Heidelberg | 25 | 13 | 12 | |
| Wiesbaden | 80 | 39 | 41 | |
| Mean age, y (range) | 48.8 (18-71) | 47.6 (18-70) | 50 (20-71) | .38 |
| Sex, no. (%) | .10* | |||
| Male | 71 | 32 (45) | 39 (55) | |
| Female | 34 | 21 (62) | 13 (38) | |
| Sedentary (< 1×/week physically active) at baseline, no. (%) | 79 | 38 (48) | 41 (52) | .66* |
| Karnofsky score t0 (median) | 90 | 90 | 90 | .40† |
| 90-100 | 82 | 43 | 39 | |
| 80-90 | 20 | 7 | 13 | |
| < 80 | 3 | 2 | 1 | |
| BMI, mean (SD) | 24.9 (4.1) | 25.1 (4.3) | 24.7 (3.9) | .66 |
| Diagnosis | ||||
| AML | 22 | 12 | 10 | |
| ALL | 14 | 6 | 8 | |
| CML | 4 | 2 | 2 | |
| CLL | 4 | 2 | 2 | |
| MDS | 12 | 7 | 5 | |
| Secondary AML | 11 | 6 | 5 | |
| MPS | 13 | 7 | 6 | |
| Multiple myeloma | 3 | 2 | 1 | |
| Other lymphomas | 20 | 7 | 13 | |
| Aplastic anemia | 2 | 1 | 1 | |
| Source of stem cell | > .999* | |||
| Bone marrow | 15 | 7 | 8 | |
| Peripheral blood cells | 90 | 45 | 45 | |
| Donor-recipient characteristics | .49* | |||
| HLA-identical (related) | 28 | 13 | 15 | |
| HLA-matched/unrelated | 56 | 26 | 30 | |
| HLA-mismatched/unrelated | 21 | 13 | 8 | |
| Conditioning regimens | ||||
| FLAMSA | 28 | 14 | 14 | |
| TBI/etoposide | 12 | 5 | 7 | |
| Flu/Bu | 11 | 7 | 4 | |
| TBI/Flu/Cyclo | 10 | 5 | 5 | |
| BCNU/Flu/Mel | 7 | 1 | 6 | |
| Flu/Bu/Cyclo | 7 | 2 | 5 | |
| TBI/Cyclo | 6 | 4 | 2 | |
| Bu/Cyclo | 5 | 4 | 1 | |
| TBI/Flu | 4 | 3 | 1 | |
| Treo/Flu | 4 | 2 | 2 | |
| Flu/Mel | 4 | 2 | 2 | |
| Flu/Cyclo | 3 | 1 | 2 | |
| TBI/Thi/Flu | 2 | 1 | 1 | |
| Cyclo | 1 | 0 | 1 | |
| Mel | 1 | 1 | 0 | |
| Intensity of conditioning regimens | .82* | |||
| Myeloablative | 24 | 11 | 13 | |
| Reduced intensity | 81 | 41 | 40 | |
| TBI | 36 | 18 | 18 | > .999* |
| GVHD incidence | 39 (37) | 21 (40) | 18 (34) | .55* |
| Skin, no. (%) | 35 (32) | 18 (35) | 17 (32) | |
| Gastrointestinal, no. (%) | 10 (10) | 5 (10) | 5 (10) | |
| Liver, no. (%) | 1 (1) | 1 (2) | 0 |
| . | All (n = 105) . | Exercise (n = 52) . | Control (n = 53) . | P . |
|---|---|---|---|---|
| Center | ||||
| Heidelberg | 25 | 13 | 12 | |
| Wiesbaden | 80 | 39 | 41 | |
| Mean age, y (range) | 48.8 (18-71) | 47.6 (18-70) | 50 (20-71) | .38 |
| Sex, no. (%) | .10* | |||
| Male | 71 | 32 (45) | 39 (55) | |
| Female | 34 | 21 (62) | 13 (38) | |
| Sedentary (< 1×/week physically active) at baseline, no. (%) | 79 | 38 (48) | 41 (52) | .66* |
| Karnofsky score t0 (median) | 90 | 90 | 90 | .40† |
| 90-100 | 82 | 43 | 39 | |
| 80-90 | 20 | 7 | 13 | |
| < 80 | 3 | 2 | 1 | |
| BMI, mean (SD) | 24.9 (4.1) | 25.1 (4.3) | 24.7 (3.9) | .66 |
| Diagnosis | ||||
| AML | 22 | 12 | 10 | |
| ALL | 14 | 6 | 8 | |
| CML | 4 | 2 | 2 | |
| CLL | 4 | 2 | 2 | |
| MDS | 12 | 7 | 5 | |
| Secondary AML | 11 | 6 | 5 | |
| MPS | 13 | 7 | 6 | |
| Multiple myeloma | 3 | 2 | 1 | |
| Other lymphomas | 20 | 7 | 13 | |
| Aplastic anemia | 2 | 1 | 1 | |
| Source of stem cell | > .999* | |||
| Bone marrow | 15 | 7 | 8 | |
| Peripheral blood cells | 90 | 45 | 45 | |
| Donor-recipient characteristics | .49* | |||
| HLA-identical (related) | 28 | 13 | 15 | |
| HLA-matched/unrelated | 56 | 26 | 30 | |
| HLA-mismatched/unrelated | 21 | 13 | 8 | |
| Conditioning regimens | ||||
| FLAMSA | 28 | 14 | 14 | |
| TBI/etoposide | 12 | 5 | 7 | |
| Flu/Bu | 11 | 7 | 4 | |
| TBI/Flu/Cyclo | 10 | 5 | 5 | |
| BCNU/Flu/Mel | 7 | 1 | 6 | |
| Flu/Bu/Cyclo | 7 | 2 | 5 | |
| TBI/Cyclo | 6 | 4 | 2 | |
| Bu/Cyclo | 5 | 4 | 1 | |
| TBI/Flu | 4 | 3 | 1 | |
| Treo/Flu | 4 | 2 | 2 | |
| Flu/Mel | 4 | 2 | 2 | |
| Flu/Cyclo | 3 | 1 | 2 | |
| TBI/Thi/Flu | 2 | 1 | 1 | |
| Cyclo | 1 | 0 | 1 | |
| Mel | 1 | 1 | 0 | |
| Intensity of conditioning regimens | .82* | |||
| Myeloablative | 24 | 11 | 13 | |
| Reduced intensity | 81 | 41 | 40 | |
| TBI | 36 | 18 | 18 | > .999* |
| GVHD incidence | 39 (37) | 21 (40) | 18 (34) | .55* |
| Skin, no. (%) | 35 (32) | 18 (35) | 17 (32) | |
| Gastrointestinal, no. (%) | 10 (10) | 5 (10) | 5 (10) | |
| Liver, no. (%) | 1 (1) | 1 (2) | 0 |
BMI indicates body mass index; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; MPS, myeloproliferative syndrome; HLA, human leukocyte antigen; FLAMSA, fludarabine Ara-C amsacrin; TBI, total body irradiation; Flu, fludarabine; Bu, busulfan; Cyclo, cyclophosphamide; BCNU, 1,3-bis (2-chloroethyl)-1-nitrosourea; Mel, melphalan; Treo, treosulfan; and Thi, thioglycollate.
Fisher exact test.
Wilcoxon test.